MAR 26·Stock Titan▲
Gain Therapeutics (NASDAQ: GANX) 2025 loss narrows as cash doubles
Gain Therapeutics reported its 2025 financial results, showing a narrowed net loss of $20.2 million compared to $20.4 million in 2024, with its cash reserves more than doubling to $20.8 million. The company also provided an update on its lead Parkinson’s disease candidate, GT-02287, highlighting encouraging Phase 1b data with central nervous system target engagement and stable or improved clinical scores. Gain Therapeutics anticipates significant milestones in 2026, including IND clearance for GT-02287 and the initiation of a Phase 2 clinical trial.
FEB 24·AD HOC NEWS→
Gain Therapeutics to Present Key Clinical Program Updates at Oppenheimer Conference
Gain Therapeutics is scheduled to present key clinical program updates at the Oppenheimer Healthcare Conference, focusing on its lead candidate GT-02287 for Parkinson's disease. The presentation, set for tomorrow, is highly anticipated for potential biomarker data that could support GT-02287's profile as a disease-modifying therapy. The market will be closely watching for implications on its Phase 2b study strategy and the stock's future movements, especially ahead of the company's Q4 earnings release on March 26.
